Search

Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches

ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US

American Thoracic Society Announces that Boehringer Ingelheim is the first donor of its COVID‐19 Crisis Fund

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Sustainability Matters: Carbon Neutral | Boehringer Ingelheim US

Find out more on how Boehringer Ingelheim are going carbon neutral at our manufacturing plant in Gainesville, Georgia, embracing sustainability.

Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation

First half 2019: High levels of investment in R&D and robust organic growth

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases

Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US

Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.

Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists

BI & Lilly Announce Outcome of FDA Advisory Meeting | Boehringer Ingelheim US

The EASE phase III program includes two Phase III clinical trials to investigate the efficacy, safety and tolerability of once-daily Empagliflozin.

2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical

Boehringer included on LinkedIn’s “Top Companies 2024” list

Investing in our people is at the core of what we do

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Boehringer Ingelheim Acquires AMAL Therapeutics

Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics

Boehringer Ingelheim and the Atlanta Humane Society mark the grand opening of a unique pet adoption center in Metro Atlanta

Transition to renewable energy signals a broader commitment to environmental sustainability

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Boehringer Ingelheim Vetmedica, Inc. to Establish North America and U.S. Headquarters in Duluth, Ga. Following Close of BI/Sanofi Asset Swap

Boehringer Ingelheim Launches External Innovation Hub in China

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches

ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Sustainability Matters: Carbon Neutral | Boehringer Ingelheim US

Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation

First half 2019: High levels of investment in R&D and robust organic growth

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases

Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US

Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists

BI & Lilly Announce Outcome of FDA Advisory Meeting | Boehringer Ingelheim US

2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound

Boehringer included on LinkedIn’s “Top Companies 2024” list

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Boehringer Ingelheim Acquires AMAL Therapeutics

Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics

Boehringer Ingelheim and the Atlanta Humane Society mark the grand opening of a unique pet adoption center in Metro Atlanta

Transition to renewable energy signals a broader commitment to environmental sustainability

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Boehringer Ingelheim Vetmedica, Inc. to Establish North America and U.S. Headquarters in Duluth, Ga. Following Close of BI/Sanofi Asset Swap

Boehringer Ingelheim Launches External Innovation Hub in China

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D